Spironolactone Treatment and Clinical Outcomes in Patients With Systolic Dysfunction and Mild Heart Failure Symptoms: A Retrospective Analysis

Department of Internal Medicine, Division of Cardiovascular Medicine at the University of Michigan, Ann Arbor, Michigan, USA.
Journal of cardiac failure (Impact Factor: 3.05). 05/2006; 12(4):250-6. DOI: 10.1016/j.cardfail.2006.01.013
Source: PubMed


The effect of spironolactone on clinical outcomes in patients with mild heart failure is unclear.
We performed a retrospective analysis of 482 consecutive patients with left ventricular ejection fraction < or =40% and New York Heart Association I-II symptoms. Major cardiac event (MCE) was defined as death, left ventricular assist device implantation, or United Network of Organ Sharing 1 cardiac transplantation. Proportional hazards analysis was used to determine predictors of MCE and to derive an adjusted hazard for spironolactone therapy. Spironolactone was prescribed to 279 (58%) patients and mean follow-up was 1029 days. After controlling for predictors of clinical events, spironolactone treatment was associated with a trend for lower risk of MCE or heart failure rehospitalization (HR, 0.68; 95% CI, 0.43-1.07; P = .095). Exploration of interaction terms between medications revealed that treatment with the combination of spironolactone and thiazide diuretics was associated with lower risk of clinical events (HR, 0.32; 95% CI, 0.12-0.89; P = .029).
In subjects with mild heart failure treated with a thiazide diuretic, the use of spironolactone is associated with reduced risk of MCE or heart failure rehospitalization. A randomized controlled trial is necessary to accurately define the clinical effects of spironolactone in patients with mild heart failure.

6 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The microstrip circuit development of an X-band, one watt, 22 dB gain GaAs FET amplifier will be discussed. Microwave performance characteristics such as intermodulation, AM to PM conversion and noise figure will be presented.
  • [Show abstract] [Hide abstract]
    ABSTRACT: THE ROLE OF ALDOSTERONE: Aldosterone is the key hormone in salt-water homeostasis. In heart failure, it participates in the appearance and maintenance of signs of congestion. Predominantly synthesised in the glomerular area of the cortico-adrenal glands, extra adrenal production areas have recently been identified notably in the brain, the heart and the large artery trunks. Aldosterone is activated in the cells by the intracellular mineral corticoid receptor. IN CARDIOVASCULAR-PATHOLOGIES: In chronic heart failure, patients treated with conversion enzyme inhibitor may escape from the renin-angiotensin blockade and this may lead to increased aldosterone plasma levels. This increase can induce not only vascular lesions and myocardial fibrosis but also renal and cerebral lesions. THE EFFECTS OF SPIRONOLACTONE: In patients with NYHA stage III or IV heart failure, addition of spironolactone to the treatment with conversion enzyme inhibitor, diuretic and/or digitalis leads to a reduction in morbidity and mortality, as demonstrated in the RALES study. The mechanisms by which spironolactone has a beneficial effect remain discussed. IN CLINICAL PRACTICE: The prescription of spironolactone is limited by hormonal side effects it provokes. IN THE FUTURE: Eplerenone, a new competitive aldosterone receptor antagonist that appears to be devoid of such side effects and which, at least experimentally may well have the same beneficial effects, is presently under clinical assessment.
    La Presse M├ędicale 02/2003; 32(2):79-87. · 1.08 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Heart failure (HF) remains a dynamic field. Treatment continues to be refined and improved and, at last, there is evidence that the increased survival demonstrated in randomized clinical trial cohorts has been translated to the unselected general population. Beyond angiotensin-converting enzyme (ACE) inhibitors and beta-blockers, two more classes of drug, the angiotensin receptor blockers and aldosterone antagonists, were unequivocally demonstrated to have a survival benefit during 2003. This year also establishes a new era in device therapies, which also improve outcomes in patients with HF.
    Journal of the American College of Cardiology 01/2005; 44(12):2398-405. DOI:10.1016/j.jacc.2004.09.070 · 16.50 Impact Factor
Show more